glp-1 agonists and sglt2 inhibitors Complementary Yet Distinct Roles of Receptor in Cardiovascular Risk Reduction Criteria for recommendation of SGLT2
Description
Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight
In clinical trials, people using GLP-1 drugs lost an average of about 10 pounds more than people using a placebo
CVOT, cardiovascular outcomes trial
In 1984, Dr
doi: 10.1111/j.1464-5491.2010.03020.x
[DOI] [PubMed] [Google Scholar] 61.Gerstein HC, et al
